Palonosetron

Generic Name
Palonosetron
Brand Names
Akynzeo, Aloxi, Palonosetron Accord
Drug Type
Small Molecule
Chemical Formula
C19H24N2O
CAS Number
135729-56-5
Unique Ingredient Identifier
5D06587D6R
Background

Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...

Indication

For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.

Associated Conditions
Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
Associated Therapies
-
Clinical Trials
Related News

PALONOSETRON X FOSAPREPITANT IN PONV

First Posted Date
2018-07-16
Last Posted Date
2019-03-12
Lead Sponsor
Hospital Federal de Bonsucesso
Target Recruit Count
100
Registration Number
NCT03586817
Locations
🇧🇷

Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

First Posted Date
2017-07-02
Last Posted Date
2024-06-25
Lead Sponsor
Helsinn Healthcare SA
Target Recruit Count
67
Registration Number
NCT03204279
Locations
🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

🇷🇺

Chelyabinsk Regional Children's Clinical Hospital, Chelyabinsk, Russian Federation

🇺🇦

National Institute of Cancer, Research Department of Pediatric Oncology, Kyiv, Ukraine

and more 14 locations

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

First Posted Date
2017-02-02
Last Posted Date
2023-10-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
53
Registration Number
NCT03040726
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

First Posted Date
2016-11-22
Last Posted Date
2016-11-23
Lead Sponsor
Hee Jun Kim
Target Recruit Count
48
Registration Number
NCT02970643

Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients

Phase 4
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Drug: palonosetron
First Posted Date
2016-10-21
Last Posted Date
2018-08-07
Lead Sponsor
Instituto Nacional de Cancer, Brazil
Target Recruit Count
80
Registration Number
NCT02941913
Locations
🇧🇷

National Cancer Institute (INCA - HCIII), Rio de Janeiro, Brazil

The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV

First Posted Date
2016-06-22
Last Posted Date
2017-07-21
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
150
Registration Number
NCT02809378
Locations
🇰🇷

Ajou universiry hospital, Suwon, Gyeonggi-do, Korea, Republic of

Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery

First Posted Date
2016-04-20
Last Posted Date
2018-06-20
Lead Sponsor
Yonsei University
Target Recruit Count
202
Registration Number
NCT02744508
Locations
🇰🇷

Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

First Posted Date
2016-01-08
Last Posted Date
2017-01-27
Lead Sponsor
Intarcia Therapeutics
Target Recruit Count
82
Registration Number
NCT02650479
Locations
🇳🇱

PRA-Groningen, Groningen, Netherlands

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Not Applicable
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Procedure: Automated recommendation at the start of the case
Procedure: Automated notification at the start of surgery
Procedure: Automated notification at the end of surgery
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Procedure: Elective surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Isoflurane
Drug: Desflurane
Drug: Scopolamine
Drug: Droperidol
Drug: Haloperidol
Drug: Dexamethasone
Drug: Promethazine
Drug: Meclizine
Drug: Aprepitant
Drug: Metoclopramide
Drug: Fentanyl
Drug: Sufentanil
Drug: Alfentanil
Drug: Remifentanil
Drug: Morphine
Drug: Meperidine
Drug: Hydromorphone
Drug: Methadone
Drug: Oxycodone
Drug: Oxymorphone
Drug: Hydrocodone
Drug: Ketamine
Drug: Ondansetron
Drug: Granisetron
Drug: Dolasetron mesylate
Drug: Palonosetron
Drug: Tropisetron
Drug: Ramosetron
First Posted Date
2015-12-09
Last Posted Date
2019-03-07
Lead Sponsor
Vanderbilt University
Target Recruit Count
27034
Registration Number
NCT02625181
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

First Posted Date
2015-11-05
Last Posted Date
2017-04-25
Lead Sponsor
Kyungpook National University Hospital
Target Recruit Count
88
Registration Number
NCT02597907
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy